This study aimed to conduct a meta-analysis to assess the clinical and microbiological efficacy of CSE-1034 for treating acute bacterial infections in adult patients. PubMed, Embase, ClinicalTrials.gov, and Cochrane databases were searched from their inception until April 2022 for relevant randomized controlled trials (RCTs). Only RCTs evaluating CSE-1034 and comparators for treating acute bacterial infections in adult patients were included. The primary outcome was the clinical response rate at the end of treatment (EOT) evaluation. Five RCTs were included. A total of 950 patients (n:638 in the UTI group, n:186 in the lower respiratory tract infection group, n:70 in the bone and joint infection group, and n:56 in SSSI) were included in this meta-analysis; 478 and 472 patients received CSE-1034 and comparators, respectively. Overall, CSE-1034 had a higher clinical cure rate at EOT than did the comparators (95.3% [384/403] vs. 81% [319/394], RR, 1.2; 95%CI, 1.04-1.39; I2=92%). Moreover, the clinical failure rate of CSE-1034 was lower than that of the comparators (RR, 0.04; 95%CI, 0.01-0.13; I2=0%). CSE-1034 also had a higher microbiological eradication rate than the comparators (92.9% [315/339] vs. 71.1% [216/304], RR, 1.53; 95%CI, 1.06-2.21; I2=97%). The clinical and microbiological efficacy of CSE-1034 is comparable or even superior in treating acute bacterial infections.
Key words: CSE-1034, acute bacterial infection, urinary tract infection, lower respiratory tract infection, community-acquired bacterial pneumonia
|
